• Pulmonary Arterial Hypertension Risk Stratification

  • 2022/07/21
  • 再生時間: 24 分
  • ポッドキャスト

Pulmonary Arterial Hypertension Risk Stratification

  • サマリー

  • Drs Vallerie McLaughlin and Ioana Preston discuss how equations and prediction models guide risk stratification of patients diagnosed with pulmonary arterial hypertension.

    Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/968547). The topics and discussions are planned, produced, and reviewed independently of advertiser. This podcast is intended only for US healthcare professionals.

    Resources

    Pulmonary Arterial Hypertension https://emedicine.medscape.com/article/303098-overview

    REVEAL Registry: Registry to Evaluate Early and Long-term PAH Disease Management https://clinicaltrials.gov/ct2/show/NCT00370214

    Predicting Survival in Pulmonary Arterial Hypertension: Insights From the Registry to Evaluate Early and Long-term Pulmonary Arterial Hypertension Disease Management (REVEAL) https://doi.org/10.1161/CIRCULATIONAHA.109.898122

    Predicting Survival in Patients With Pulmonary Arterial Hypertension: The REVEAL Risk Score Calculator 2.0 and Comparison With ESC/ERS-Based Risk Assessment Strategies https://doi.org/10.1016/j.chest.2019.02.004

    Development and Validation of an Abridged Version of the REVEAL 2.0 Risk Score Calculator, REVEAL Lite 2, for Use in Patients With Pulmonary Arterial Hypertension https://doi.org/10.1016/j.chest.2020.08.2069

    REVEAL Lite 2 Risk Calculator https://pahriskcalculatorlt.com/

    Brain-Type Natriuretic Peptide (BNP) https://emedicine.medscape.com/article/2087425-overview

    2015 ESC/ERS Guidelines for the diagnosis and Treatment of Pulmonary Hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT) https://doi.org/10.1093/eurheartj/ehv317

    Risk Assessment in Pulmonary Arterial Hypertension https://erj.ersjournals.com/content/51/3/1702606

    A Comprehensive Risk Stratification at Early Follow-up Determines Prognosis in Pulmonary Arterial Hypertension https://doi.org/10.1093/eurheartj/ehx257

    Risk Assessment, Prognosis and Guideline Implementation in Pulmonary Arterial Hypertension https://doi.org/10.1183/13993003.00889-2017

    Risk Assessment in Pulmonary Arterial Hypertension https://doi.org/10.1183/13993003.02606-2017

    Regular Risk Assessment in Pulmonary Arterial Hypertension - A Whistleblower for Hidden Disease Progression https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8888324

    A Pragmatic Approach to Risk Assessment in Pulmonary Arterial Hypertension Using the 2015 European Society of Cardiology/European Respiratory Society Guidelines https://openheart.bmj.com/content/8/2/e001725.long

    Risk Assessment in Precapillary Pulmonary Hypertension: A Comparative Analysis https://respiratory-research.biomedcentral.com/articles/10.1186/s12931-021-01624-z

    Diagnostic and Predictive Value of Right Heart Catheterization-Derived Measurements in Pulmonary Hypertension https://doi.org/10.36740/WLek202103130

    Scleroderma https://emedicine.medscape.com/article/331864-overview

    COMPERA 2.0: A Refined 4-Strata Risk Assessment Model for Pulmonary Arterial Hypertension https://doi.org/10.1183/13993003.02311-2021

    続きを読む 一部表示

あらすじ・解説

Drs Vallerie McLaughlin and Ioana Preston discuss how equations and prediction models guide risk stratification of patients diagnosed with pulmonary arterial hypertension.

Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/968547). The topics and discussions are planned, produced, and reviewed independently of advertiser. This podcast is intended only for US healthcare professionals.

Resources

Pulmonary Arterial Hypertension https://emedicine.medscape.com/article/303098-overview

REVEAL Registry: Registry to Evaluate Early and Long-term PAH Disease Management https://clinicaltrials.gov/ct2/show/NCT00370214

Predicting Survival in Pulmonary Arterial Hypertension: Insights From the Registry to Evaluate Early and Long-term Pulmonary Arterial Hypertension Disease Management (REVEAL) https://doi.org/10.1161/CIRCULATIONAHA.109.898122

Predicting Survival in Patients With Pulmonary Arterial Hypertension: The REVEAL Risk Score Calculator 2.0 and Comparison With ESC/ERS-Based Risk Assessment Strategies https://doi.org/10.1016/j.chest.2019.02.004

Development and Validation of an Abridged Version of the REVEAL 2.0 Risk Score Calculator, REVEAL Lite 2, for Use in Patients With Pulmonary Arterial Hypertension https://doi.org/10.1016/j.chest.2020.08.2069

REVEAL Lite 2 Risk Calculator https://pahriskcalculatorlt.com/

Brain-Type Natriuretic Peptide (BNP) https://emedicine.medscape.com/article/2087425-overview

2015 ESC/ERS Guidelines for the diagnosis and Treatment of Pulmonary Hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT) https://doi.org/10.1093/eurheartj/ehv317

Risk Assessment in Pulmonary Arterial Hypertension https://erj.ersjournals.com/content/51/3/1702606

A Comprehensive Risk Stratification at Early Follow-up Determines Prognosis in Pulmonary Arterial Hypertension https://doi.org/10.1093/eurheartj/ehx257

Risk Assessment, Prognosis and Guideline Implementation in Pulmonary Arterial Hypertension https://doi.org/10.1183/13993003.00889-2017

Risk Assessment in Pulmonary Arterial Hypertension https://doi.org/10.1183/13993003.02606-2017

Regular Risk Assessment in Pulmonary Arterial Hypertension - A Whistleblower for Hidden Disease Progression https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8888324

A Pragmatic Approach to Risk Assessment in Pulmonary Arterial Hypertension Using the 2015 European Society of Cardiology/European Respiratory Society Guidelines https://openheart.bmj.com/content/8/2/e001725.long

Risk Assessment in Precapillary Pulmonary Hypertension: A Comparative Analysis https://respiratory-research.biomedcentral.com/articles/10.1186/s12931-021-01624-z

Diagnostic and Predictive Value of Right Heart Catheterization-Derived Measurements in Pulmonary Hypertension https://doi.org/10.36740/WLek202103130

Scleroderma https://emedicine.medscape.com/article/331864-overview

COMPERA 2.0: A Refined 4-Strata Risk Assessment Model for Pulmonary Arterial Hypertension https://doi.org/10.1183/13993003.02311-2021

Pulmonary Arterial Hypertension Risk Stratificationに寄せられたリスナーの声

カスタマーレビュー:以下のタブを選択することで、他のサイトのレビューをご覧になれます。